1,756
Participants
Start Date
April 6, 2022
Primary Completion Date
January 31, 2027
Study Completion Date
March 31, 2028
Ketamine
The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
Etomidate
The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
Wake Forest Baptist Medical Center, Winston-Salem
University of Alabama Hospital, Birmingham
Vanderbilt University Medical Center, Nashville
Hennepin County Medical Center, Minneapolis
University of Colorado Denver, Aurora
Denver Health Medical Center, Denver
Patient-Centered Outcomes Research Institute
OTHER
Vanderbilt University Medical Center
OTHER